Background: This trial evaluated whether a combination of docetaxel and gemcitabine provides better survival than docetaxel alone in patients with previously treated non-small-cell lung cancer (NSCLC). Results: Sixty-five patients participated in each arm. This trial was terminated early due to an unexpected high incidence of interstitial lung disease (ILD) and three treatment-related deaths due to ILD in the combination arm. Docetaxel plus gemcitabine compared with docetaxel-alone patients experienced similar grade and incidence of toxicity, except for ILD. No baseline factor was identified for predicting ILD. Median survival times were 10.3 and 10.1 months (one-sided P = 0.36) for docetaxel plus gemcitabine and docetaxel arms, respectively.
introduction
Lung cancer is the most common cancer worldwide, with an estimated 1.2 million new cases globally (12.3% of all cancers) and 1.1 million deaths (17.8% of all cancer deaths) in 2000 [1] . The estimated global incidence of non-small-cell lung cancer (NSCLC) in 2000 was 1 million, which accounted for 80% of all cases of lung cancer [1] . Treatment of advanced NSCLC is palliative; the aim is to prolong survival without leading to deterioration in quality of life [2] . The recommended first-line treatment of advanced NSCLC currently involves up to four cycles of platinum-based combination chemotherapy, with no single combination recommended over others [3] . Although this treatment improves survival rates, a substantial proportion of patients do progress and should be offered second-line treatment. With unsurpassed efficacy compared with other chemotherapeutic regimens or best supportive care [4, 5] , docetaxel alone is the current standard as second-line chemotherapy for advanced NSCLC. The recommended regimen of docetaxel 75 mg/m 2 given i.v. every 3 weeks as second-line therapy has been associated with median survival times of 5.7-7.5 months [4, 5] and is also associated with better quality-of-life outcomes compared with best supportive care [2] . Docetaxel monotherapy for recurrent NSCLC after platinum-based chemotherapy has several limitations, however, including low response rates (7-11%), brief duration of disease control, and minimal survival advantage [4, 5] .
Gemcitabine is also active against recurrent NSCLC after platinum-based chemotherapy [6] . Gemcitabine 1000 mg/m 2 once a week for 3 weeks every 28 days produced a 19% response rate in a phase II trial, and it shows significant activity mainly in patients previously responsive to chemotherapy [6] . Singleagent gemcitabine has a low toxicity profile and is well tolerated [6] .
Docetaxel and gemcitabine have distinct mechanisms of action and nonoverlapping toxic effects except for neutropenia. Many studies of the combination of docetaxel and gemcitabine have been conducted in first-and second-line settings [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . The following doses and schedule have been adopted in most studies: docetaxel 80-100 mg/m 2 on day 1 or 8 and gemcitabine 800-1000 mg/m 2 on days 1 and 8 or on days 1, 8, and 15. Furthermore, most studies required use of prophylactic granulocyte colony-stimulating factor (G-CSF) support.
In Japan, however, the recommended dose of docetaxel is 60 mg/m 2 every 3 weeks [17, 18] . Several studies to confirm the dose and schedule of this combination without prophylactic G-CSF support have been conducted in Japan [19] [20] [21] . Two studies recommended docetaxel 60 mg/m 2 on day 8 and gemcitabine 800 mg/m 2 on days 1 and 8, and another study recommended docetaxel 50 mg/m 2 on day 8 and gemcitabine 1000 mg/m 2 on days 1 and 8, without prophylactic G-CSF support, every 3 weeks. These studies demonstrated the consistent promising efficacy of this combination regimen. An objective response was observed in 28%-40% of patients, with a median survival time of 11.1-11.9 months and a 1-year survival rate of 41%-47%.
We conducted a multicenter, randomized, phase III trial to evaluate whether the combination regimen of docetaxel and gemcitabine provides better survival than docetaxel alone in patients with previously treated NSCLC.
patients and methods

patient selection
Eligible patients were 20-75 years of age, with histologically or cytologically confirmed stage IIIB (with malignant pleural effusion or contralateral hilar lymph node metastases) or stage IV NSCLC who had failed one platinumbased chemotherapy regimen previously. Patients who had received gemcitabine or docetaxel were excluded. Additional inclusion criteria included a Eastern Cooperative Oncology Group performance status of zero to one, and adequate organ function as indicated by white blood cell count ‡4000/ll, absolute neutrophil count ‡2000/ll, hemoglobin ‡9.5 g/dl, platelets ‡100 000/ll, aspartate aminotransferase (AST)/alanine amonotransferase (ALT) £2.5 times the upper limit of normal, total bilirubin £1.5 mg/dl, serum creatinine £1.2 mg/dl, and PaO 2 in arterial blood ‡70 torr. Asymptomatic brain metastases were allowed provided that they had been irradiated and were clinically and radiologically stable. Prior thoracic radiotherapy was allowed provided that treatment was completed at least 12 weeks before enrollment. Patients were excluded from the study if they had radiologically and clinically apparent interstitial pneumonitis or pulmonary fibrosis. All patients provided written informed consent, and the study protocol was approved by Japan Clinical Oncology Group (JCOG) Clinical Trial Review Committee and the institutional review board of each participating institution.
treatment plan and dose modifications
Eligible patients were centrally registered at JCOG Data Center and were randomly assigned to either docetaxel 60 mg/m 2 as a 60-min i.v. infusion on day 1 or docetaxel 60 mg/m 2 as a 60-min i.v. infusion on day 8 plus gemcitabine 800 mg/m 2 as a 30-min i.v. infusion on days 1 and 8, using a minimization method with institutions and response to prior chemotherapy (progressive disease or not) as balancing factors. Patients receiving docetaxel were administered standard dexamethasone premedication (8 mg orally at the day before, on the day, and the day after docetaxel administration) as previously reported [7] and 50 mg of diphenhidramine 30 min before docetaxel administration. Recombinant human G-CSF was not given prophylactically. Chemotherapy cycles were repeated every 3 weeks until disease progression. Docetaxel was given before gemcitabine in the docetaxel plus gemcitabine regimen. Dose adjustments were based mainly on hematologic parameters. The doses of docetaxel and gemcitabine were reduced by 10 and 200 mg/m 2 , respectively, in subsequent cycles if chemotherapy-induced febrile neutropenia, grade 4 anemia, grade 4 thrombocytopenia, grade 4 leukopenia, or grade 4 neutropenia lasting for >3 days occurred in the absence of fever. Dose reductions were maintained for all subsequent cycles. Patients requiring more than one dose reduction were off-protocol treatment.
baseline and follow-up assessments Pretreatment evaluation included a complete medical history and physical examination, a complete blood count (CBC) test with differential and platelet count, standard biochemical profile, electrocardiogram, chest radiographs, computed tomographic scans of the chest, abdomen, and brain, magnetic resonance imaging, and a whole-body bone scan. During treatment, a CBC and biochemical tests were carried out weekly. A detailed medical history was taken and a complete physical examination with clinical assessment was carried out weekly to assess disease symptoms and treatment toxicity, and chest radiographs were done every treatment cycle. Toxicity was evaluated according to the National Cancer Institute Cancer-Common Toxicity Criteria Version 2 [22] .
All patients were assessed for response by computed tomography scans after every two cycles of chemotherapy. Response Evaluation Criteria in Solid Tumors (RECIST) were used for the evaluation of response [23] .
The progression-free survival (PFS) was calculated from the day of randomization until the day of the first evidence of disease progression or death. If the patient had no progression, PFS was censored at the day when no clinical progression was confirmed. Overall survival (OS) was measured from the day of randomization to death.
Disease-related symptoms were evaluated and scored at baseline and 6 weeks after the start of treatment with the seven-item Lung Cancer Subscale (LCS) of the Functional Assessment of Cancer Therapy-Lung version 4 [24] , which were translated from English to Japanese. The questionnaire entries were listed as follows: 'I have been short of breath', 'I am losing weight', 'My thinking is clear', 'I have been coughing', 'I have a good appetite', 'I feel tightness in my chest', and 'Breathing is easy for me'. Patients scored using a five-point Likert scale (0-4) by themselves. The maximum attainable score of the LCS was 28, where the patient was considered to be asymptomatic.
statistical analysis
The primary endpoint was OS; secondary endpoints were PFS, the overall response rate, disease-related symptoms, and toxicity profile. Based on previous trials evaluating the docetaxel [4, 5] and docetaxel plus gemcitabine [19] [20] [21] regimens, the present study was designed to detect a 12% difference of 1-year survival rate. To attain an 80% power at a onesided significance level of 0.05, assuming 1-year survival of docetaxel arm as 35% with 1 year of follow-up after 2 years of accrual, 284 patients (142 per each arm) were required. Analyses were to be carried out with all randomized patients. Both the OS and PFS were estimated with the Kaplan-Meier method. The comparisons of OS and PFS between arms were assessed by the stratified log-rank test with a factor used at randomization, response to prior chemotherapy. Two interim analyses were planned after half of the patients were registered and the end of registration.
For the symptom analysis, changes of LCS from initial score were compared between arms using analysis of covariance with initial score as a covariate.
All analyses were carried out with SAS software release 8.2 (SAS Institute, Cary, NC).
results
This trial was terminated early due to the unexpected high incidence of interstitial lung disease (ILD) and three treatmentrelated deaths due to ILD in the combination arm, which were identified by the Adverse Event Reporting system.
patient characteristics
From January 2002 to September 2003, 130 patients with NSCLC who had failed prior platinum-based chemotherapy from 32 institutions were enrolled (Appendix). These patients were randomly assigned to docetaxel alone (n = 65) or docetaxel plus gemcitabine (n = 65). One patient died as a result of rapid progressive disease before chemotherapy administration, and one patient did not meet the entry criteria in the docetaxel arm. In addition, one patient did not meet the entry criteria in the docetaxel plus gemcitabine arm. All patients were included in the analysis of survival and PFS, and 64 docetaxel and 65 docetaxel plus gemcitabine patients were assessable for toxicity. Fifty-nine patients with measurable lesions by RECIST in the docetaxel arm and 57 eligible patients in docetaxel plus gemcitabine arm were assessable for response (Figure 1) . Table 1 presents baseline patient characteristics.
The median number of cycles was 3 (range 0-6) and 2 (range 1-8) in the docetaxel and docetaxel plus gemcitabine arms, respectively. The median interval between cycles was 22 days for both arms.
toxicity
This trial was terminated early due to the unexpected high incidence of ILD and three treatment-related deaths (4.6%) due to ILD in the docetaxel plus gemcitabine arm. These events were identified by the Adverse Event Reporting system. Thirteen (20.0%) patients receiving combination treatment suffered from all grades of ILD, whereas only two (3.1%) patients receiving docetaxel alone suffered from grades 1-2 ILD. Grades 2-4 ILD occurred in 16.9% of docetaxel plus gemcitabine patients, an unexpected high incidence rate. No risk factors were identified contributing to these pulmonary adverse events.
Toxicity was assessed in all patients who received at least one treatment cycle and in all cycles (Table 2) . Overall, grades 3-4 neutropenia occurred in 55 docetaxel patients (85.9%) and 53 docetaxel plus gemcitabine patients (81.5%). Grades 3-4 anemia occurred in two patients (3.1%) and 12 patients (18.5%) treated with docetaxel alone and docetaxel plus (Table 2) . Overall, docetaxel plus gemcitabine was more toxic than docetaxel, however, well tolerated except for ILD in docetaxel plus gemcitabine arm.
treatment efficacy
The overall response rate for docetaxel alone was 6.8% [95% confidence interval (CI) 1.9% to 16 .5%] and 7.0% for docetaxel plus gemcitabine (95% CI 2.0% to 17.0%). There was no significant difference between treatment arms (P = 0.71; Fisher's exact test). At the time of this analysis, 50 docetaxel patients (76.9%) and 48 docetaxel plus gemcitabine patients (73.8%) had died. The median survival time was 10.1 months for docetaxel alone and 10.3 months for docetaxel plus gemcitabine (one-sided P = 0.36 stratified log-rank test; Figure 2A ). The respective 1-year survival rate was 43.1% (95% CI 31.0% to 55.1%) for docetaxel and 46.0% (95% CI 33.8% to 58.1%) for docetaxel plus gemcitabine.
The median PFS time was 2.1 and 2.8 months for docetaxel and docetaxel plus gemcitabine, respectively (onesided P = 0.028 stratified log-rank test; Figure 2B ). 
disease-related symptom assessment
Patients' compliance with disease-related symptom assessment was 100% at baseline and 95.4% at 6 weeks later. Compliance rates were not different between the arms (P = 1.00). LCS data were missing in four surveys due to death or severe impairment of the patient's general condition; this accounted for 1.5% of the total number of surveys scheduled. Mean LCS at baseline and 6 weeks were shown in Table 3 . There were no significant differences in the LCS changes from baseline to 6 weeks between docetaxel and docetaxel plus gemcitabine arms (P = 0.61).
discussion
This trial was terminated early due to the unexpected high incidence of ILD and three treatment-related deaths due to ILD in the docetaxel plus gemcitabine arm. Our findings seem to indicate that the combination of docetaxel and gemcitabine may be associated with a higher incidence of pulmonary adverse events compared with docetaxel alone, especially in patients with previously treated NSCLC. Pulmonary toxicity following chemotherapeutic agents, including ILD, has been well recognized for many years. In most cases, this toxicity is mild and self-limiting. However, the mechanism of developing drug-induced ILD is uncertain, and risk factors for developing this disorder have not been identified. In terms of combination therapy with docetaxel and gemcitabine for advanced NSCLC, there were few reports about the incidences of ILD at the time this study was planned. A phase I study of patients with transitional cell carcinoma evaluated thrice-weekly doses of docetaxel given on day 1 plus gemcitabine given on days 1 and 15 and showed that pulmonary toxicity occurred in three of five patients and was the cause of death in one [25] . Recently, some reports have been published about the high incidence of ILD due to the combination regimen of docetaxel and gemcitabine in patients with NSCLC [13, 26, 27] , including the present study (Table 4) . In Japanese population, ILD is a very complex issue in treatment of patients with lung cancer. Epidermal growth factor tyrosine kinase inhibitor gefitinib is developing ILD significantly in Japanese patients with NSCLC [28] . It is uncertain why ILD is developing more in Japanese patients with NSCLC than the Western patients. Ethnic difference may be one of the explanations for this occurrence. The combination of gemcitabine and docetaxel is associated with a high incidence of severe pulmonary toxicity. The regimen should not be used outside a clinical trial.
The median survival times of 10.1 and 10.3 months and estimated 1-year survival rates of 43.1% and 46.0% with docetaxel alone and docetaxel plus gemcitabine, respectively, suggest that adding gemcitabine to docetaxel did not provide any increased efficacy in patients with previously treated NSCLC. Interestingly, the combination regimen of docetaxel plus gemcitabine significantly improved the median PFS time (P = 0.028). Possible reasons for failing to detect a significant difference between survival curves may include an insufficient occurrence of documented events as a result of the study population comprising patients with relatively good prognosis, in addition to a high proportion of patients subsequently receiving third-line therapy. During this study, gefitinib treatment was commonly used for patients with recurrent NSCLC in Japan [29] . Asian ethnicity is a well-known predictive factor for a response for gefitinib [30] .
Two randomized phase II trials compared docetaxel alone with docetaxel plus irinotecan in second-line chemotherapy for NSCLC [31, 32] . No significant treatment differences in survival were observed in either trial; however, the trials were phase II study and were not powered or designed to compare survival. This study was not powered to compare survival when it was terminated early due to the unexpected high incidence of ILD in the docetaxel plus gemcitabine arm. However, based on previous studies, as well as the present results, combination chemotherapy with docetaxel and another chemotherapeutic agent has not improved survival in patients with previously treated NSCLC.
In conclusion, docetaxel alone is still the standard secondline treatment for advanced NSCLC. The combination of docetaxel and gemcitabine was too toxic to obtain any survival 
